Thursday, Virax Biolabs Group Limited (NASDAQ: VRAX) announced it is launching 'ImmuneSelect' within the ViraxImmune T-Cell diagnostic platform for research-use-only (RUO) at the European Society of Clinical Microbiology and Infectious Diseases Global 2024 Congress.

"We are very pleased to launch ImmuneSelect, an important portfolio of immune profiling solutions within our ViraxImmune T-Cell diagnostic platform," commented Mr. James Foster, Chief Executive Officer of Virax Biolabs.

"The launch marks a significant milestone for Virax, as it brings us a step closer to commercializing ViraxImmune as a full in-Vitro Diagnostic product."

ImmuneSelect is the company's new portfolio of immune profiling solutions dedicated to investigating adaptive immunity.

ImmuneSelect is developed to evaluate T-Cell driven immunity and to aid in the understanding and early characterization of symptoms associated with post-viral syndromes, including Long COVID.

Products within the ImmuneSelect brand are for research and investigational use only and are not intended to be used as a diagnostics tool.

The ImmuneSelect portfolio includes peptide pools covering epitopes from pathogens linked to post-viral syndromes.

These include pools for SARS-CoV-2, SARS-CoV-2 MHC-1 (CD8), Lyme Disease, Cytomegalovirus, Respiratory Syncytial Virus, and Epstein-Barr Virus.

ImmuneSelect's Recombinant Antibodies target cytokines and biomarkers, and they are available in different versions unconjugated to be tested on a range of applications, including Flow Cytometry, ELISA, and ELISpot/Fluorospot.

Dr. Nigel McCracken, the Chief Operations Officer of Virax Biolabs, said, "We believe there is great potential to utilize T-Cell diagnostics to help detect underlying post-viral infections by initially measuring the body's adaptive immune resistance to infections and then monitoring the potential progression of an individual's T-Cell functions following chronic antigen stimulation."

Price Action: VRAX shares closed at $0.66 on Wednesday.